immunocytochemistry: suitable, indirect ELISA: suitable, microarray: suitable, western blot: 1-2 μg/test using nuclear extract of cultured human acute T cell leukemia Jurkat cells or MCF7 cells
Methyl-CpG binding protein 2 (MeCP2) possesses a methyl-CpG-binding domain (MBD) and a transcriptional repression domain.
Monoclonal Anti-MeCP2 (mouse IgG1 isotype) is derived from the Men-8 hybridoma produced by the fusion of mouse myeloma cells (NS1) and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to the N-terminus of human MeCP2.
Immunogen
synthetic peptide corresponding to the N-terminus (amino acids 15-30) of human MeCP2.
Application
Monoclonal Anti-MeCP2 antibody has been used:
in western blotting
in immunoblotting
in flow cytometry
in immunohistofluorescence
in immunocytochemistry
Biochem/physiol Actions
MeCP2 (methyl-CpG binding protein 2) silences transcription by recruiting the histone deacetylase (HDAC) repressive machinery via recruitment of the Sin 3A corepressor, thus removing acetyl groups from histones and consequently, silencing genes.
Methyl-CpG binding protein 2 (MeCP2) has been shown be crucial for brain development. It part of the methyl-CpG-binding proteins, which are involved in repression of gene expression by binding to methylated DNA. Mutations in the gene encoding MeCP2 have been associated with Rett syndrome (RTT).
Physical form
Solution in 0.01 M phosphate buffered saline containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.